A few weeks ago, we wrote about a positive test for latent tuberculosis and treating that infection with antibiotics. On the heels of that column, we received some follow-up questions from readers.

A previous analysis examined the public health impact of new tuberculosis vaccines and predicted that a pre-exposure vaccine, targeting the acquisition of infection or primary progression would be ...

A highly anticipated trial of a tuberculosis vaccine yields disappointing results. A vaccine designed to protect infants against tuberculosis (TB) isn’t as effective as researchers had hoped. The ...

A team of scientists led by Oxford University have made a discovery that could improve our chances of developing an effective vaccine against Tuberculosis. The researchers have identified new ...

A large-scale screen of tuberculosis proteins has revealed several possible antigens that could be developed as a new vaccine for TB, the world's deadliest infectious disease. In the new study, a team ...

A two-dose regimen of the M72/AS01 E-4, a recombinant fusion protein tuberculosis vaccine candidate, demonstrated acceptable safety and immunogenicity in virally suppressed, antiretroviral therapy ...

While all eyes have been focused on the race to develop a COVID-19 vaccine, other researchers have been furiously working on another way to defeat the coronavirus. It's a vaccine with a very long ...

TOKYO, Feb. 2, 2026 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximately JPY 1.39 billion (USD 8.8 million (1) ) in six R&D projects ...